peoplePerson
Pamela S. Ohashi
Immunologist who built Canada's TIL therapy programme and defined T-cell tolerance mechanisms.
Leads the Tumour Immunotherapy Program at Princess Margaret, running TIL trials in melanoma and other solid tumours and studying T-cell activation thresholds.
Role
Director, Tumour Immunotherapy Program; Co-Director, Campbell Family Institute for Breast Cancer Research
Institution
Specialisms
T-cell toleranceTIL therapyTumour immunology
Profiles
| Title | Journal | Year |
|---|---|---|
| Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice | Cell | 1991 |
Pages like this
not linked directly; found by shared links- PersonShari Pilon-Thomas
Shares TIL therapy, Melanoma.
- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Melanoma.
- CollectionMelanoma Research Alliance (MRA)
Shares TIL therapy, Melanoma.
- PersonPatrick Hwu
Shares TIL therapy, Melanoma.
- PersonAmod A. Sarnaik
Shares TIL therapy, Melanoma.
- TrialC-144-01
Shares TIL therapy, Melanoma.
- InstitutionCentre hospitalier de l'Université de Montréal (CHUM)
Shares TIL therapy, Melanoma.
- InstitutionCancer Center Clínica Universidad de Navarra / CIMA
Shares TIL therapy, Melanoma.